Connect Biopharma Holdings Ltd

Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company based in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra, in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). The company was founded in 2012 and is headquartered in San Diego, California.